SCHEMBL21114403

SCHEMBL21114403

O=C(O)Cc1ccc(OC(=O)Cc2ccc(O)cc2)cc1

nearest known ligand 0.68

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CA2 P00918 2/20 0.68
CAMK2A Q9UQM7 1/20 0.68
SENP1 Q9P0U3 2/20 0.53
CYP19A1 P11511 1/20 0.51
KMT2A Q03164 4/20 0.50
THRA P10827 1/20 0.50
THRB P10828 1/20 0.50
UCHL1 P09936 1/20 0.49
USP5 P45974 1/20 0.49
USP4 Q13107 1/20 0.49
ASAH1 Q13510 1/20 0.48
FNTA P49354 1/20 0.47
FNTB P49356 1/20 0.47
HPGD P15428 1/20 0.47
SRD5A2 P31213 1/20 0.46
TMPRSS2 O15393 1/20 0.46
KLK1 P06870 1/20 0.46
PRSS1 P07477 1/20 0.46
AKR1B1 P15121 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL414384 0.93 SENP1 (0.59) CA2CAMK2ASENP1CYP19A1KMT2A
SCHEMBL417739 0.87 CYP19A1 (0.67) CA2CAMK2ASENP1CYP19A1KMT2A
SCHEMBL417740 0.87 SENP1 (0.62) CA2CAMK2ASENP1CYP19A1KMT2A
SCHEMBL13893855 0.84 KMT2A (0.68) SENP1KMT2AHPGD
SCHEMBL2353788 0.83 CA2 (0.76) CA2CAMK2AKMT2ATHRATHRB
SCHEMBL8081742 0.83 SENP1 (0.57) CA2CAMK2ASENP1CYP19A1KMT2A
SCHEMBL75700 0.82 CA2 (1.00) CA2CAMK2ATHRATHRBFNTA
SCHEMBL21114405 0.82 CA2 (1.00) CA2CAMK2ATHRATHRBFNTA
Hydrogen Peroxide SCHEMBL27765042 0.82 CA2 (1.00) CA2CAMK2ATHRATHRBFNTA
Methane SCHEMBL6154008 0.80 CA2 (0.95) CA2CAMK2ATHRATHRBFNTA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190214145-A1 Method and systems for creating and screening patient metabolite profile to diagnose current medical condition, diagnose current treatment state and recommend new treatment regimen KUREK ITZHAK (US) 2019-07-11 US disclosed